Breast milk Δ9-tetrahydrocannabinol in cannabis users during the postpartum period: correlation between breast milk, maternal urine and saliva samples during early lactation - Report - MDSpire

Breast milk Δ9-tetrahydrocannabinol in cannabis users during the postpartum period: correlation between breast milk, maternal urine and saliva samples during early lactation

  • By

  • Miguel Sandonís

  • Maia Brik

  • Clara Ramirez

  • Laura Castellote

  • Anna Creus

  • Gemma Parramón

  • Anna Suy

  • Josep Antoni Ramos-Quiroga

  • Raul Felipe Palma-Álvarez

  • Constanza Daigre

  • June 30, 2026

  • 0 min

Share

Clinical Report: Analysis of Δ9-tetrahydrocannabinol Levels in Breast Milk

Overview

This study evaluates Δ9-THC concentrations in breast milk, saliva, and urine among postpartum women using cannabis. Findings indicate that Δ9-THC levels in breast milk decline rapidly after cessation of cannabis use, becoming non-quantifiable within the first week postpartum.

Background

The increasing prevalence of cannabis use among pregnant and postpartum women raises significant concerns regarding maternal and infant health. Understanding the pharmacokinetics of Δ9-THC in breast milk is crucial for providing evidence-based guidance to breastfeeding mothers who use cannabis. Current guidelines recommend avoiding cannabis during lactation due to potential risks to infants.

Data Highlights

Sample TypeΔ9-THC ConcentrationTime Point
Breast MilkDecreased over time, non-quantifiable by 1 week24 hours, 48 hours, 1 week postpartum
SalivaGenerally low, often below LOQ24 hours, 48 hours, 1 week postpartum
Urine (THC-COOH)Progressively decreased but quantifiable24 hours, 48 hours, 1 week postpartum

Key Findings

  • Δ9-THC concentrations in breast milk decreased rapidly after cannabis cessation.
  • Breast milk Δ9-THC became non-quantifiable within one week postpartum among abstinent participants.
  • Urinary THC-COOH concentrations remained quantifiable longer than breast milk Δ9-THC.
  • Salivary Δ9-THC concentrations were low and frequently below the limit of quantification.
  • Significant correlations were observed between breast milk Δ9-THC and salivary Δ9-THC at the first sampling stage.
  • No significant correlations were found at later stages of the study.

Clinical Implications

Healthcare providers should be aware of the rapid decline of Δ9-THC in breast milk following cannabis cessation.

Conclusion

The study suggests that further research is needed to confirm findings on Δ9-THC levels in breast milk.

Related Resources & Content

  1. ACOG, Cannabis Use During Pregnancy and Lactation, 2025 -- Clinical Consensus
  2. LactMed, Cannabis - Drugs and Lactation Database, NCBI -- Summary of THC in Breast Milk
  3. Frontiers in Psychiatry, Breast milk Δ9-tetrahydrocannabinol in cannabis users during the postpartum period, 2026 -- Article
  4. Archives of Toxicology — Impact of Tetrahydrocannabinol from Cannabis on Endocannabinoid Balance in Human Placental Tissue
  5. Archives of Toxicology — Celebrating 85 Years of Cannabis Research Publications in Archives of Toxicology
  6. Frontiers in Pediatrics — Clinical study design and modeling approaches to study secretion of drugs in human milk
  7. The Journal of Infectious Diseases — CD8+ T Cells in Breast Milk: Key Players in Immune Protection Against Human Cytomegalovirus Transmission
  8. Cannabis Use During Pregnancy and Lactation | ACOG
  9. Cannabis - Drugs and Lactation Database (LactMed®) - NCBI Bookshelf
  10. Frontiers | Breast milk Δ9-tetrahydrocannabinol in cannabis users during the postpartum period: correlation between breast milk, maternal urine and saliva samples during early lactation

Original Source(s)

Related Content